SRTA
Strata Critical Medical, Inc.·Industrials
4.12
1.980%(+0.08)
Close PriceLast Updated: — ET
52W L: $2.5152W H: $6.02
SRTA NEWS
globenewswire.com
4d ago
Strata Critical Medical to Present at the 25th Annual Needham Virtual Healthcare Conference
NEW YORK, April 09, 2026 (GLOBE NEWSWIRE) -- Strata Critical Medical, Inc. (Nasdaq: SRTA, “Strata” or the “Company”), today announced that management will present at the 25th Annual Needham Virtual Healthcare Conference on Wednesday, April 15, 2026, at 1:30 pm ET. A webcast of the event will be available at the link here.
seekingalpha.com
Mar 17
Strata Critical Medical: Significant Upside Potential Backed By Robust EBITDA Growth
Strata Critical Medical is rated 'Buy' with a 12–24 month horizon, targeting 30–35% upside as valuation remains attractive despite a recent rally. SRTA's transformation into a pure-play medical logistics provider, robust FY25 results, and margin expansion underpin confidence in forward guidance. Industry tailwinds, regulatory catalysts, and an aggressive acquisition strategy position SRTA for sustained revenue and EBITDA growth, with FY26 guidance implying an 11.6% EBITDA margin.
seekingalpha.com
Mar 3
Strata Critical Medical, Inc. (SRTA) Q4 2025 Earnings Call Transcript
Strata Critical Medical, Inc. (SRTA) Q4 2025 Earnings Call Transcript
globenewswire.com
Mar 3
Strata Critical Medical Announces Fourth Quarter 2025 Results
Revenue increased 83.5% year-over-year to $66.8 million in Q4 2025 Logistics revenue and gross profit grew 35.3% and 39.5% year-over-year, respectively, in Q4 2025, which represents Strata's organic growth Full year 2025 net loss from continuing operations was $20.1 million Full year 2025 revenue and Adjusted EBITDA (1) of $197.1 million and $14.1 million, respectively, both beat the high end of our guidance range Raising full year 2026 revenue guidance to between $260 and $275 million and Adjusted EBITDA guidance to between $29 and $33 million (2) NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Strata Critical Medical, Inc. (Nasdaq: SRTA, "Strata" or the "Company"), today announced financial results for the fourth quarter ended December 31, 2025. Financial results in this release, including all comparisons to prior year periods, reflect continuing operations only.
globenewswire.com
Feb 10
Strata Critical Medical Schedules Fourth Quarter 2025 Earnings Conference Call
NEW YORK, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Strata Critical Medical (Nasdaq: SRTA, “Strata” or the “Company”), will release financial results for the fourth quarter ended December 31, 2025 on Tuesday, March 3, 2026 before the market opens. The company will hold a conference call on the same day at 8:00 am Eastern Time to discuss the results. The call will be hosted by Will Heyburn, Strata's Co-Chief Executive Officer and Chief Financial Officer, and Melissa Tomkiel, Strata's Co-Chief Executive Officer and General Counsel, and will include a question-and-answer session for call participants.
globenewswire.com
Feb 5
Strata Announces Closing of Revolving Credit Facility to Support Acquisition Strategy Execution
$30 million ABL Facility will support future acquisitions and be undrawn at close; can be increased to $50 million, subject to certain conditions Owned aircraft excluded from collateral package and remain unencumbered NEW YORK, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Strata Critical Medical, Inc. (Nasdaq: SRTA, “Strata” or the “Company”), a leading provider of logistics and medical services in the organ transplant industry, today announced that the Company has entered into a credit agreement with JPMorgan Chase Bank, N.A. for secured, asset-based revolving credit loans in aggregate principal amount of up to $30.0 million, which, subject to certain conditions, may be increased up to an aggregate of $50.0 million (the “ABL Facility”).
